Evaluation of role of doxycycline (a matrix metalloproteinase inhibitor) on renal functions in patients of diabetic nephropathy

Renal Failure

Volumn 32, Issue 8, 2010, Pages 941-946

  Aggarwal, Hari Krishan ^a   Jain, Deepak ^a   Talapatra, Paulomi ^a   Yadav, Raj Kumar ^a   Gupta, Tarana ^a   Kathuria, Kashmiri Lal ^a  

^a PT B D SHARMA UNIVERSITY OF HEALTH SCIENCES   (India)

Author keywords

Diabetic nephropathy; Doxycycline; Matrix metalloproteinase inhibitor; Proteinuria; Renal functions

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXYCYCLINE; HEMOGLOBIN; INSULIN; MATRIX METALLOPROTEINASE INHIBITOR; ORAL ANTIDIABETIC AGENT; PHOSPHATE; PLASMA PROTEIN; PROTEIN; UREA; URIC ACID;

ADULT; ARTICLE; BLOOD PRESSURE; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIABETIC NEPHROPATHY; DRUG EFFICACY; ENZYME INHIBITION; FEMALE; GLOMERULUS FILTRATION RATE; GLYCEMIC CONTROL; HUMAN; KIDNEY FUNCTION; LOW DRUG DOSE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROTEINURIA; RENAL PROTECTION; UREA BLOOD LEVEL; URIC ACID BLOOD LEVEL;

ADOLESCENT; ADULT; AGED; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTI-BACTERIAL AGENTS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DOXYCYCLINE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; KIDNEY FUNCTION TESTS; MALE; MATRIX METALLOPROTEINASES; MIDDLE AGED; PROTEINURIA; YOUNG ADULT;

EID: 77955928306     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2010.502606     Document Type: Article

References (26)

1. Barit D, Cooper ME. Diabetic patients and kidney protection: An attainable target. J Hypertens. 2008;26:53-57.
2. Schrijvers B, De Urieso AS, Flyobjerg A. From hyperglycemia to diabetic kidney disease. Endocr Rev. 1997;25:971-1010.
3. Toshio D. The current clinical problems for early phase of diabetic nephropathy and progression. Kidney Int. 1995;48: 1929-1935.
4. Fioretto P, Steffes MW, Mauer SM. Glomerular structure in non proteinuric IDDM patients with various levels of albuminuria. Diabetes. 1994;43:1358-1364.
5. Chavers BM, Bilous RW, Elis EN, Steffes MW, Mauer SM. Glomerular lesions and urinary albumin excretion in type I diabetes without overt proteinuria. N Engl J Med. 1989;320: 966-970.
6. Fioretto P, Steffes MW, Sutherland DE, Mauery M. Sequential renal biopsies in IDDM patients; structural factors associated with clinical progression. Kidney Int. 1995;48:1929-1935.
7. Zaoui P, Cantin JF, Alimardani Bassette M, et al. Role of MMPs and inhibitors in the occurrence and progression of diabetic renal lesions. Diabetes Metab. 2000;26:25-29.
8. Han SY, Jee YH, Han KH, et al. An imbalance between matrix metalloproteinase-2 and tissue inhibitor of matrix metalloproteinase-2 contributes to the development of early diabetic nephropathy. Nephrol Dial Transplant. 2006;21: 2406-2416.
9. Wahab NA, Harper K, Manson RM. Expression of extracellular matrix molecules in human, mesangial cells in response to prolonged hyperglycemia. Biochem J. 1996;316:985-992.
10. Sharma K, Zi Yodeah FN. Hyperglycemia and diabetic kidney disease: The care for TGF b as a key mediator. Diabetes. 1995;44:1139-1146.
11. Franco C, Bernard HO, Mullholland D, Hou G, Guignabert C. Doxycycline alters vascular smooth muscle cell adhesion, migration and reorganization of fibrillar collagen matrices. Am J Pathol. 2006;168:1697-1709.
12. Naini AE, Harandi AA, Moghtaderi J, Bartani B, Amiran A. Doxycycline: A pilot study to reduce diabetic proteinuria. Am J Nephrol. 2007;27:269-273.
13. Pradeepa R, Deepa R, Mohan V. Epidemiology of diabetes in India-Current perspective and future projections. J Indian Med Assoc. 2002;100:144-148.
14. The Diabetes Control and Complications trial research group. The effect of intensive treatment of diabetes on the development and progression of long term complications in IDDM. N Engl J Med. 1993;329:977-986.
15. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of angiotensin receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Eng J Med. 2001;345:851-860.
16. Brenner BM, Cooper ME, Dezeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Eng J Med. 2001;345:861-869.
17. Pedrini MT, Levey AS, Lau J, Chalmers TC, Wang PH. The effect of dietary protein restriction on the progression of diabetic and non diabetic renal disease: A meta-analysis. Ann Intern Med. 1996;124:627-632.
18. Wilens SL, Elster SK. The role of lipid deposition in renal arteriolar sclerosis. Am J Med Sci. 1951;219:183-196.
19. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227-239.
20. Laville M. New strategies in anaemia management; Anaemia Corrections in Diabetes (ACORD) trial. Acta Diabetol. 2004; 41:18-22.
21. Kelly DJ, Zhang Y, Hepper C, et al. Protein kinase C b inhibition attenuates the progression of experimental diabetic nephropathy in the presence of continued hypertension. Diabetes. 2003;52:512-518.
22. Trachtman H, Schwob N, Maesaka J, Valderama E. Vitamin E supplementation ameliorates renal injury in chronic puromycin aminoglycoside nephropathy. J Am Soc Nephrol. 1995;5:1811-1819.
23. Zaoui D, Kim Y, Steffes MW, Groppoli TJ, Butkowski RJ, Mauer SM. Glomerular distribution of type IV collagen in diabetes by high resolution quantitative immunochemistry. Kidney Int. 1994;45:425-4233.
24. Nakamura T, Ushiyama C, Suzuki S, et al. Urinary excretion of podocytes in patients with diabetic nephropathy. Nephrol Dial Transplant. 2000;15:1379-1383.
25. Ahuja TS. Doxycycline decreases proteinuria in glomerulonephritis. Am J Kidney Dis. 2003;42:376-380.
26. McLennan SV, Kelly DJ, Schache M, et al. Advanced glycation end products decrease mesangial cell MMP-7: A role in matrix accumulation in diabetic nephropathy. Kidney Int. 2007;72:481-488.